Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.2%

7 terminated/withdrawn out of 46 trials

Success Rate

81.1%

-5.4% vs industry average

Late-Stage Pipeline

7%

3 trials in Phase 3/4

Results Transparency

0%

0 of 30 completed trials have results

Key Signals

2 recruiting7 withdrawn

Enrollment Performance

Analytics

Phase 3
2(33.3%)
Phase 2
2(33.3%)
Phase 4
1(16.7%)
N/A
1(16.7%)
6Total
Phase 3(2)
Phase 2(2)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (46)

Showing 20 of 46 trials
NCT07352878Not Yet Recruiting

Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.

Role: lead

NCT06949956Not Yet Recruiting

Administration of Fingolimod in Greek Patients With Multiple Sclerosis.

Role: lead

NCT06528613Recruiting

Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.

Role: lead

NCT06117722Recruiting

TorasEmide Induced Effect on QoL and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone.

Role: lead

NCT06399341Completed

Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).

Role: lead

NCT06170125Not Yet Recruiting

QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt.

Role: lead

NCT03858348Completed

A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination

Role: lead

NCT03299673Completed

AdHerencE to Treatment and quAlity of Life in COPD

Role: lead

NCT04835961Completed

AdditioN of Fixed Dose Combination (FDC) Of Budesonide/Formoterol Via Elpenhaler® Device in Greek Patients With asThma accΟrding to Standard Clinical Practice.

Role: lead

NCT01484210Phase 3Completed

Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®

Role: lead

NCT05168215Unknown

Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.

Role: lead

NCT01484327Completed

Carvedilol Vascular Efficacy Trial

Role: lead

NCT04831476Completed

Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)

Role: lead

NCT05426915Unknown

Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.

Role: lead

NCT03947866Unknown

Ezetimibe-Rosuvastatin Evaluation Study

Role: lead

NCT03873584Withdrawn

Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy

Role: lead

NCT03873571Withdrawn

Adherence of Iron Succinylate Therapy in Pregnancy

Role: lead

NCT05459194Not ApplicableCompleted

Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler

Role: lead

NCT03033758Completed

Evaluation of the Effectiveness and Quality of Life With the Administration of the Fixed Combination of Budesonide Formoterol in Greek Patients With Asthma During Routine Clinical Practice.

Role: lead

NCT04902183Phase 2Unknown

Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19

Role: collaborator